Adsa Logo White Adsa Title White

The effect of a mycotoxin deactivator on the vitamin and mineral status of lactating dairy cows.

J. Faas

Events

06-23-2020

Join J. Faas on this page for a live text chat!
6:00 PM - 8:00 PM GMT

Abstract:

T118
The effect of a mycotoxin deactivator on the vitamin and mineral status of lactating dairy cows.
J. Faas*1, B. Doupovec1, R. Nicole1, A. Gallo2, Q. Zebeli3, D. Schatzmayr1. 1BIOMIN Research Center Tulln, Austria, 2Department of Animal Science, Food and Nutrition (DIANA) Facolt� di Scienze Agrarie, Alimentari e Ambientali Universit� Cattolica del Sacro Cuore Piacenza, Italy, 3Institute of Animal Nutrition and Functional Plant Compounds and Institute for Food Safety, Food Technology and Veterinary Public Health, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Austria.

When using a mycotoxin deactivator product (MDP) one possible downfall could be the unspecific and undesired binding of vitamins and minerals. The objective of these 2 trials was to evaluate the in vivo effect of application of an MDP product on blood levels of vitamins and minerals in lactating dairy cows. For the first trial (trial 1), 12 Holstein cows in mid-lactation were used in a 3x3 4 times replicated Latin square design. Cows received either an uncontaminated TMR (CTR), a TMR contaminated with Fusarium mycotoxins (MTX), or the contaminated TMR supplemented with an MDP (35 g/animal/day) (MDP). Each of the experimental periods consisted of a 3-week treatment period followed by a 2-week clearance period. For the second trial (trial 2), a total of 20 Simmental cows in mid-lactation were assigned to either a control group (CTR) or a treatment group (MDP) receiving 60 g/head/day of the same MDP as in trial 1 for 7 d. In either trial, blood samples were taken from each animal before the administration of the product, during and/or at the end of the product application (D0, D14 and D21 in trial 1 and D0 and D7 in trial 2). Blood samples were analyzed for calcium, chloride, magnesium, phosphate, potassium, sodium and zinc in both trials 1 and 2 and for vitamins A, D3, B1, B2, B6 and B12, as well as copper, iron, manganese and selenium in trial 2. In trial 1, data were analyzed as repeated measurements using the MIXED procedure of SAS 9.3. The data of trial 2 were analyzed using independent-samples t-test in SPSS 22.0. We did not detect a significant difference between treatments for any measured parameters in either trial. For example, the levels of manganese or vitamin B12 did not differ significantly between treatment groups in trial 2 at D7 (Manganese: CTR: 3.76 � 1.46 ng/L vs. MDP 4.17 � 0.81 ng/L P = 0.63, Vitamin B12: 1CTR 29.05 � 40.70 �g/L vs. MDP 159.41 � 37.54 �g/L, P = 0.56). In conclusion, the administration of this specific MDP did not affect the levels of vitamins or minerals in the blood of dairy cows suggesting that at this inclusion levels no undesired binding took place.

Keywords: mycotoxin deactivator product, vitamins, minerals.